
    low recruitment of patients
  
['urinary incontinence', 'overactive bladder']
['placebo', 'placebo']

        Key Inclusion Criteria:

          -  Urinary Incontinence for at least 3 months prior to Screening as a result of
             Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.

          -  Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or
             below which occurred at least 6 months prior to Screening.

          -  Subjects with Multiple Sclerosis must be clinically stable in the investigator's
             opinion, with no exacerbation (relapse) of MS for at least 3 months prior to
             Screening.

          -  Subjects must have had an inadequate response after at least 4 weeks of oral
             medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists)
             and/or have intolerable side-effects.

          -  Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate
             bladder emptying.

          -  An average of at least two episodes per day of Urinary Incontinence recorded on the
             screening bladder diary.

        Key Exclusion Criteria:

          -  Any current condition (other than NDO) that may impact on bladder function.

          -  Previous or current, tumour or malignancy affecting the spinal column or spinal cord,
             or any other unstable cause of SCI.

          -  Any condition that will prevent cystoscopic treatment administration or CIC usage,
             e.g. urethral strictures.

          -  Current indwelling bladder catheter, or removal of indwelling bladder catheter less
             than 4 weeks prior to Screening.

          -  BTX-A treatment within 9 months prior to Screening for any urological condition (e.g.
             detrusor or urethral sphincter treatments).

          -  Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within
             4 weeks prior to Screening. Any implanted neuromodulation device must be switched off
             at least 4 weeks prior to Screening.
      